Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

Published:2015-07-10 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Ahn Daniel H.,Li Junan,Wei Lai,Doyle Austin,Marshall John L.,Schaaf Larry J.,Phelps Mitch A.,Villalona-Calero Miguel A.,Bekaii-Saab Tanios

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep12122.pdf

Reference31 articles.

1. Khan, S. A., Thomas, H. C., Davidson, B. R. & Taylor-Robinson, S. D. Cholangiocarcinoma. Lancet 366, 1303–1314 (2005).

2. Goydos, J. S., Brumfield, A. M., Frezza, E., Booth, A., Lotze, M. T. & Carty, S. E. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227, 398–404 (1998).

3. Park, J., Tadlock, L., Gores, G. J. & Patel, T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30, 1128–1133 (1999).

4. Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362, 1273–1281 (2010).

5. Kruth, J. et al. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder and bile duct carcinoma. J Cancer Res Clin Oncol 136, 1845–1851 (2010).

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling pathways in liver cancer: pathogenesis and targeted therapy;Molecular Biomedicine;2024-05-31

2. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26

3. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies;Current Cancer Drug Targets;2024-03

4. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma;Pharmaceutics;2023-08-14

5. Molecular Pathways in Gallbladder Cancer as Potential Therapeutic Target;Gallbladder Cancer;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3